Alixia is focused on addressing cancer drug resistance by treating tumors as dynamic ecosystems rather than merely targeting specific mutations. Their approach recognizes that cancer is not just a single mutation problem but an ecological one, where various cell types within the tumor microenvironment interact and compete for resources. This complexity necessitates a broader strategy that considers factors such as mechanical stress, inflammatory signals, and metabolic changes. Alixia's research platform aims to identify molecules that can disrupt these interactions, thereby collapsing the tumor ecosystem and enhancing treatment efficacy.

The company is developing tumor ecosystem disruptors that target both cancerous and quasi-cancerous cells by addressing metabolic and inflammatory triggers within the microenvironment. By impacting multiple cell types, Alixia seeks to enable more effective and lasting cancer treatments. Their therapeutic portfolio is derived from the intersections of cancer, aging, and immunity, and includes programs aimed at various age-related diseases. Alixia integrates disciplines such as biology, biophysics, and computational chemistry to drive innovation in therapeutic development, with a dedicated team of scientists and clinicians committed to transforming medicine and improving patient outcomes.

United States

Alixia is a medical research company that engages in developing new modalities to treat cancer, aging, and inflammation.

Alixia

Company Details